Literature DB >> 20930679

Aortic valve replacement by ministernotomy in redo patients with previous left internal mammary artery patent grafts.

Roberto Gaeta1, Salvatore Lentini, Giuseppe Raffa, Carlo Pellegrini, Giuseppe Zattera, Mario Viganò.   

Abstract

OBJECTIVE: Aortic valve surgery with a patent left internal mammary artery (LIMA) on the left anterior descending (LAD) coronary artery is challenging in terms of myocardial protection and graft injury. Minimally invasive techniques may require minimal dissection of adhesions and may eventually decrease the risk of injuries.
METHODS: Since 1997, more than 1000 ministernotomies have been performed by our surgical unit. Of these, 16 patients (14 males, 2 females, mean age: 68.7 years) had a patent LIMA graft on LAD. Fourteen underwent native aortic valve replacement, and in 2 a previously implanted prosthesis was replaced. A miniresternotomy was performed using either a "J" (15 patients) or a "reversed-T" method (1 patient).
RESULTS: Cardiopulmonary bypass (CPB) was achieved by either femoral vein (12 patients) or right atrium (4 patients); arterial inflow was achieved either by ascending aorta (12 patients) or by femoral artery (4 patients). Mean CPB time was 119.7 ± 38.1 minutes (range: 50-235). Mean cooling body temperature was 27.4 °C. Antegrade cold crystalloid cardioplegia was delivered to all the patients. Mean aortic cross-clamp time was 72 ± 20 minutes (range: 45-125). No damage to LIMA occurred in any of the patients. No intra- or perioperative myocardial infarction (MI) occurred. Neither a conversion to full sternotomy nor a reoperation for bleeding was needed. Mean postoperative bleeding was 426 ± 474 ml (range: 120-1950). A blood transfusion was necessary in 7 patients. Mean postoperative ICU stay was 1.6 ± 1.1 days. Mean postoperative hospital stay was 7.5 ± 2.6 days. Postoperative course was totally uneventful in 10 patients (58.8%). Follow-up was complete for a total of 928 patient/months (range: 11-124), and there were four late deaths, two of which were related to cardiac problems. Nine of the 12 survivors are in NYHA CLASS I . II. Prosthesis-related morbidity did not occur either early or late during follow-up.
CONCLUSIONS: This experience may represent the feasibility of an alternative surgical approach to a standard full-length median sternotomy in patients with previous coronary revascularization and with a patent LIMA on the LAD, requiring new surgery on the aortic valve.

Entities:  

Mesh:

Year:  2010        PMID: 20930679

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  6 in total

Review 1.  Is a minimally invasive approach for re-operative aortic valve replacement superior to standard full resternotomy?

Authors:  Andrés M Pineda; Orlando Santana; Gervasio A Lamas; Joseph Lamelas
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-05-07

Review 2.  Minimally invasive reoperative aortic valve replacement: a systematic review and meta-analysis.

Authors:  Kevin Phan; Jessie J Zhou; Nithya Niranjan; Marco Di Eusanio; Tristan D Yan
Journal:  Ann Cardiothorac Surg       Date:  2015-01

3.  Minimally invasive reoperative aortic valve replacement.

Authors:  Elisa Mikus; Simone Calvi; Alberto Tripodi; Luca Dozza; Mauro Lamarra; Mauro Del Giglio
Journal:  Ann Cardiothorac Surg       Date:  2015-01

Review 4.  Reoperative minimal access aortic valve replacement.

Authors:  Tsuyoshi Kaneko; Marzia Leacche; John Byrne; Lawrence Cohn
Journal:  J Thorac Dis       Date:  2013-11       Impact factor: 2.895

5.  Surgery of the Ascending Aorta with or without Combined Procedures through an Upper Ministernotomy: Outcomes of a Series of More Than 100 Patients.

Authors:  Salvatore Lentini; Luigi Specchia; Salvatore Nicolardi; Federica Mangia; Olivera Rasovic; Giuseppe Di Eusanio; Renato Gregorini
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-11-13       Impact factor: 1.520

Review 6.  Minimally invasive aortic valve replacement in high risk patient groups.

Authors:  Daniel Fudulu; Harriet Lewis; Umberto Benedetto; Massimo Caputo; Gianni Angelini; Hunaid A Vohra
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.